# Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

> **NCT04634916** · NA · RECRUITING · sponsor: **C. R. Bard** · enrollment: 280 (estimated)

## Conditions studied

- Kidney Disease, End-Stage
- End-stage Renal Disease
- Arteriovenous Fistula

## Interventions

- **DEVICE:** EndoAVF Creation

## Key facts

- **NCT ID:** NCT04634916
- **Lead sponsor:** C. R. Bard
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-26
- **Primary completion:** 2027-06
- **Final completion:** 2027-09
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04634916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04634916, "Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04634916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*